1,2,3,4-Tetra-O-benzoyl-L-fucopyranose - CAS 140223-15-0
Category:
Carbohydrates
Product Name:
1,2,3,4-Tetra-O-benzoyl-L-fucopyranose
CAS Number:
140223-15-0
Molecular Weight:
580.58
Molecular Formula:
C34H28O9
COA:
Inquire
MSDS:
Inquire
Structure:
Monosaccharides
Chemical Structure
CAS 140223-15-0 1,2,3,4-Tetra-O-benzoyl-L-fucopyranose

Related Monosaccharides Products


Reference Reading


1.Membrane permeabilizing action of amphidinol 3 and theonellamide A in raft-forming lipid mixtures.
Espiritu RA. Z Naturforsch C. 2016 May 9. pii: /j/znc.ahead-of-print/znc-2016-0043/znc-2016-0043.xml. doi: 10.1515/znc-2016-0043. [Epub ahead of print]
Amphidinol 3 (AM3) and theonellamide A (TNM-A) are potent antifungal compounds produced by the dinoflagellate Amphidinium klebsii and the sponge Theonella spp., respectively. Both of these metabolites have been demonstrated to interact with membrane lipids ultimately resulting in a compromised bilayer integrity. In this report, the activity of AM3 and TNM-A in ternary lipid mixtures composed of 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (POPC):brain sphingomyelin:cholesterol at a mole ratio of 1:1:1 or 3:1:1 exhibiting lipid rafts coexistence is presented. It was found that AM3 has a more extensive membrane permeabilizing activity compared with TNM-A in these membrane mimics, which was almost complete at 15 μM. The extent of their activity nevertheless is similar to the previously reported binary system of POPC and cholesterol, suggesting that phase separation has neither beneficial nor detrimental effects in their ability to disrupt the lipid bilayer.
2.Whole-Body Barometric Plethysmography Characterizes Upper Airway Obstruction in 3 Brachycephalic Breeds of Dogs.
Liu NC1, Adams VJ2, Kalmar L1, Ladlow JF1, Sargan DR1. J Vet Intern Med. 2016 May 9. doi: 10.1111/jvim.13933. [Epub ahead of print]
BACKGROUND: A novel test using whole-body barometric plethysmography (WBBP) was developed recently to diagnose brachycephalic obstructive airway syndrome (BOAS) in unsedated French bulldogs.
3.Galectin-3 and prediction of therapeutic response to renal sympathetic denervation.
Schwerg M1, Eilers B2, Wienecke A1, Baumann G1, Laule M1, Knebel F1, Stangl K1, Stangl V1. Clin Exp Hypertens. 2016 May 9:1-5. [Epub ahead of print]
The profibrotic mediator Galectin-3 (Gal-3) has been associated with aldosterone-mediated vascular inflammation, fibrosis, and stiffness. We evaluated whether the Gal-3 levels and change in Gal-3 as associated with renal denervation can serve as prediction of therapeutic response to renal denervation. A total of 42 patients with resistant hypertension undergoing renal sympathetic denervation (RDN) were included. Blood pressure was evaluated by 24-h ambulatory measurement before RDN and 1, 3 and 6 months after RDN. Treatment response was defined as a drop in systolic ambulatory blood pressure of >5 mm Hg after 6 months. Blood samples were assessed for Gal-3 levels. For the entire group, a significant drop in mean systolic ambulatory blood pressure of 5.2 ± 18.6 mm Hg was observed (p = 0.032). The responder rate was 50% (n = 21). At baseline, Gal-3 levels were significantly higher in responders (14.5 ± 6.0 vs. 10.95 ± 4.6 ng/ml, p = 0.017).